Anthem Biosciences
Anthem Biosciences
HealthcareKey Fundamentals
MidcapBiotechnologyHealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 118 days to 92.3 days
Weaknesses
2- Stock is trading at 15.8 times its book value
- Promoter holding has decreased over last quarter: -3.25%
Growth Rate
AI Analysis — Bull vs Bear
Anthem Biosciences is a Healthcare-sector company with a market capitalisation of about ₹49,626 crore. It trades at a P/E of 86.6 and a P/B of 16.39, backed by a 3-year sales CAGR of 26%, a 3-year profit CAGR of 21% and last-year ROE of 22%, on a nearly debt-free balance sheet. TTM sales fell 2% while TTM profit rose 18%, and promoter holding dropped 3.25% in the last quarter.
- Sales grew at a 26% CAGR over 3 years, faster than the 5-year CAGR of 14%. Growth has sped up in recent years.
- Profit grew at a 21% CAGR over 3 years and 17% over 5 years, showing steady compounding in the medium term.
- Return on equity has stayed high and stable: 22% last year, 21% over 3 years and 23% over 5 years. Growth has not come at the cost of capital efficiency.
- TTM profit grew 18% even though TTM sales fell 2%. This points to better margins or a better revenue mix, not growth driven only by volume.
- Working capital days fell from 118 to 92.3, a drop of about 22%. That frees up cash and improves how efficiently operations turn into cash.
- The company is almost debt-free and has cut its debt. This lowers financial risk and leaves room to fund capex or client-driven capacity expansion.
- The stock has returned 12% over 1 year, so the market has held its valuation premium over that period.
- At a P/E of 86.6, the earnings yield is only about 1.15%. The price already assumes strong growth will continue for years.
- A P/B of 16.39 on a market cap of about ₹49,626 crore implies a book value of roughly ₹3,030 crore. Buyers are paying a large premium over net assets.
- TTM sales fell 2%, a sharp reversal from the 26% 3-year sales CAGR. At this valuation, the market may react strongly if the top line keeps slowing.
- Promoter holding fell 3.25% in the last quarter. That adds shares to the market and may raise questions about how insiders see the valuation.
- The P/E of 86.6 against a 3-year profit CAGR of 21% gives a PEG of about 4.1. The valuation is well ahead of historical earnings growth.
- The dividend yield is only 0.23%, so returns depend almost entirely on the price going up, with little income cushion.
- There is limited trading history: 3-, 5- and 10-year stock CAGR data are unavailable and no 52-week high/low was provided. This makes it harder to judge how the stock behaves across market cycles.
- The 18% TTM profit growth came alongside a 2% sales decline. If the margin gains came from one-off mix or cost factors, they may not repeat without revenue growth.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
- Upside sharing arrangement settled Sep 8
Anthem Biosciences settled an upside sharing arrangement of ₹1,276.83 million with its principal shareholders after Viridity Tone LLP divested its stake. Public shareholders had approved the arrangement.
TL;DR: The only recent news is a one-off governance and accounting event: a ₹1,276.83 million upside sharing arrangement with principal shareholders was settled after Viridity Tone LLP divested its stake, with public shareholder approval. The settlement doesn't show any change in operations, so it gives no read on business strength or new risks. The stake sale may signal some exit by early shareholders, though the public shareholder approval and the closing of the obligation reduce overhang. Investors should watch upcoming quarterly results, CRDMO order wins and any further shareholding changes for a clearer view of where the stock is heading.
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| PBT | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.9 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
Profit & Loss
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,002 |
| Expenses | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,290 | 1,209 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% | 40% |
| Other Income | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 133 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 138 |
| PBT | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 783 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% | 28% | — |
| Net Profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS in Rs | 111 | 320 | 462 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 19% | — |
Balance Sheet
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 54 |
| Other Liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 333 |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Fixed Assets | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 |
| Other Assets | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
Cash Flow
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Investing | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Financing | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO/OP | 116 | 85 | 81 | 98 | 51 | 64 | 126 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
| ROCE % | — | 55% | 51% | 28% | 24% | 28% | 30% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Anthem Biosciences insights
64 extracted metrics + investor summaries across FY19–FY27.
Documents
Frequently Asked Questions about Anthem Biosciences
What does Anthem Biosciences Ltd do?
Where is Anthem Biosciences Ltd (ANTHEM) listed?
Which sector does Anthem Biosciences Ltd belong to?
What is the market capitalisation of Anthem Biosciences Ltd?
What is the PE ratio of Anthem Biosciences Ltd?
What is the 52-week high and low of Anthem Biosciences Ltd?
Does Anthem Biosciences Ltd pay dividends?
What is the Return on Equity (ROE) of Anthem Biosciences Ltd?
Company Information
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ANTHEM.md for Anthem Biosciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.